来氟米特在治疗伴外周关节炎的强直性脊柱炎中的作用分析  

The Effect Analysis of Leflunomide in the Treatment of Ankylosing Spondylitis with Peripheral Arthritis

作　　者：邱敏丽[1] 潘云峰[1] 方霖楷[1] 古洁若[1] 

机构地区：[1]中山大学附属第三医院,广东广州510630

出　　处：《中国医学创新》2013年第27期28-29,共2页Medical Innovation of China

摘　　要：目的:探讨来氟米特(LEF)在治疗伴外周关节炎的强直性脊柱炎(AS)中的效果和安全性。方法:将150例伴有外周关节炎的活动性AS患者随机分为LEF组、柳氮磺胺吡啶(SASP)组和安慰剂对照组,分别接受相应治疗,疗程24周,观察AS病情控制情况和不良反应发生率。结果:LEF能显著降低AS患者的BASDAI指数、外周关节压痛数及肿胀数,显著提高ASAS20改善率,疗效与SASP组相当。LEF组不良反应发生率显著低于SASP组,但与对照组差异无显著性。结论:LEF能够有效控制伴外周关节炎AS患者病情,安全性好。Objective： To observe the efficacy and safety of lellunomide （ LEF ） in the treatment of Ankylosing Spondylitis （ AS ） with peripheral arthritis. Method： 150 patients with active AS with peripheral arthritis were randomized at baseline to receive LEF or SASP or placebo for 24 weeks. The curative effect and the incidence of adverse reactions among the three groups were compared. Result： LEF could significantly reduce the BASI）AI index and the tender and swelling peripheral joints counts of AS. And the rate of ASAS20 improvement was significantly elevated. The efficacy of the LEF group was not different compared with the SASP group, but the adverse reactions incidence of LEF was significantly lower than SASP, not different from the placebo. Conclusion： Using LEF in the treatment of AS with peripheral arthritis has shown that it is effective and safe.

关 键 词：来氟米特 强直性脊柱炎 疗效 不良反应 

分 类 号：R593.23[医药卫生—内科学]